# IO Biotech, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/IO Biotech, Inc.). ## Overview IO Biotech, Inc. is a clinical-stage biopharmaceutical company developing therapeutic cancer vaccines, with its lead program IO102-IO103 now referred to in the U.S. as Cylembio® (imsapepimut and etimupepimut, adjuvanted). The company is focused on advancing oncology immunotherapy candidates through clinical trials and regulatory approval, with no approved products or product revenue to date. ## Products & services • Cylembio® (imsapepimut and etimupepimut, adjuvanted) • IO102-IO103 therapeutic cancer vaccine platform • Preclinical oncology vaccine candidates • Clinical development services for internal pipeline • Regulatory and commercialization preparation for future products - **Lead therapeutic cancer vaccine** (0%) — Clinical-stage vaccine program targeting oncology indications, including Cylembio®/IO102-IO103. - **Pipeline development programs** (0%) — Earlier-stage preclinical and discovery assets intended to expand the oncology pipeline. - **Clinical and regulatory development** (100%) — Internal R&D, trial execution, and regulatory work needed to advance candidates toward approval. - Cylembio® (imsapepimut and etimupepimut, adjuvanted) - IO102-IO103 therapeutic cancer vaccine candidate - Preclinical oncology vaccine programs - Clinical trial development and execution - Regulatory approval and launch preparation ## Customers IO Biotech does not yet sell approved products, so it currently has no commercial customer base. Its future customers would be oncology physicians, hospitals, and treatment centers if Cylembio® or other candidates reach approval, while near-term stakeholders are regulators, clinical investigators, and potential collaborators. - **Oncology treatment providers** (primary) — Hospitals, cancer centers, and physicians would buy or administer approved therapies if the pipeline succeeds. - **Patients with solid tumors** (primary) — End users of the therapy, especially in indications addressed by IO102-IO103/Cylembio®. - **Regulatory authorities** (secondary) — FDA and foreign agencies evaluate the clinical package and determine whether products can be commercialized. - **Strategic collaborators** (secondary) — Pharma partners may fund, co-develop, or commercialize programs and provide non-dilutive capital. - Oncology physicians who would prescribe approved cancer vaccines - Hospitals and cancer centers that administer treatment - Patients with cancers targeted by the vaccine programs - Regulators reviewing safety and efficacy data - Potential pharma collaborators or license partners ## Geography The company is headquartered in the United States, but its operating footprint is international, with references to Denmark and European financing through the EIB loan facility. Its clinical and regulatory work is tied to U.S. and foreign oncology markets, and future commercialization would likely depend on approvals and reimbursement across multiple jurisdictions. - United States is the key market for clinical and future commercialization - Denmark is an important operating base for the company - European Union exposure includes EIB financing and cross-border operations - Clinical and regulatory work spans U.S. and foreign jurisdictions - Future sales would depend on reimbursement systems in multiple countries ## Strategy IO Biotech’s strategy is to advance Cylembio® through late-stage clinical development and generate the data needed for regulatory approval. The company is also focused on preserving liquidity through equity, debt, collaborations, and non-dilutive funding while it remains pre-revenue and capital intensive. - **Complete clinical development of Cylembio®** (short-term) — Approval depends on positive late-stage data and successful trial execution. - **Secure additional capital** (short-term) — Current cash is not sufficient to fund all planned development activities. - **Prepare for commercialization** (medium-term) — If approved, the company must build or outsource sales, marketing, and distribution. - Advance Cylembio® through Phase 3 and other clinical trials - Build evidence for regulatory approval in oncology indications - Seek collaborations, licenses, and non-dilutive funding - Manage cash carefully while funding R&D and trial execution - Prepare for future commercialization capabilities or partners ## Risks IO Biotech is a pre-revenue oncology developer with substantial clinical, regulatory, financing, and commercialization risk. Its lead asset may fail in later-stage trials, approval may be delayed or denied, and the company may need more capital before it can reach commercialization or even continue as a going concern. - **Clinical development failure** [critical] — The lead candidate is still in development and early results may not predict later outcomes. - **Going concern and financing risk** [critical] — The company expects to need additional capital to fund future clinical and preclinical work. - **Commercialization execution risk** [high] — The company has no sales, marketing, or distribution infrastructure. - **Manufacturing and supply chain risk** [high] — Specialty materials and contract manufacturing are needed for clinical and commercial supply. - **Competitive and technological obsolescence** [high] — Oncology is crowded and faster or better therapies could reduce market opportunity. - No approved products, so revenue depends on future clinical success - Late-stage trial failure could eliminate the lead program's value - Additional funding may be unavailable or highly dilutive - Commercial launch would require building or outsourcing sales capability - Manufacturing and supply chain complexity could delay trials or launch - Intense oncology competition could make the platform less competitive ## Accounting The company’s financial reporting is dominated by judgment-heavy estimates typical of a pre-commercial biotech, especially going concern assessment, R&D cost recognition, and tax valuation allowances. Because it has no product revenue, reported results are driven by operating expense timing, financing transactions, and fair value accounting for warrants and equity-linked instruments. - **Going concern** — Affects financial statement presentation and investor assessment of survival risk - **Research and development expense recognition** — Drives reported loss and masks underlying progress until commercialization - **Valuation allowance on deferred tax assets** — Prevents tax benefits from reducing reported losses - **Equity and warrant fair value accounting** — Can materially affect equity and non-cash expense recognition - Going concern assessment depends on future funding and trial spending - R&D costs are expensed as incurred, driving large operating losses - Full valuation allowance recorded against deferred tax assets - Warrants and bundled equity issuances require fair value allocation - No product revenue yet, so results are highly dependent on financing --- *Last updated: 2026-04-28T20:16:36.753594+00:00*